Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.82 |
| ▸ | RIPK1 | Q13546 | 12/20 | 0.77 |
| ▸ | MAPT | P10636 | 3/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.73 |
| ▸ | MEN1 | O00255 | 2/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.73 |
| ▸ | NPC1 | O15118 | 4/20 | 0.67 |
| ▸ | RAB9A | P51151 | 3/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | CASP3 | P42574 | 1/20 | 0.59 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.59 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.59 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9378251 | 0.88 | RIPK1 (0.68) | POLBRIPK1MAPTALDH1A1MEN1 | |
| SCHEMBL30679210 | 0.85 | MAPT (1.00) | POLBRIPK1MAPTALDH1A1MEN1 | |
| SCHEMBL30679211 | 0.85 | MAPT (1.00) | POLBRIPK1MAPTALDH1A1MEN1 | |
| SCHEMBL29135188 | 0.85 | MAPT (1.00) | POLBRIPK1MAPTALDH1A1MEN1 | |
| SCHEMBL29135189 | 0.85 | MAPT (1.00) | POLBRIPK1MAPTALDH1A1MEN1 | |
| SCHEMBL23800957 | 0.84 | RIPK1 (0.71) | POLBRIPK1MAPTALDH1A1MEN1 | |
| SCHEMBL23808092 | 0.84 | RIPK1 (0.65) | POLBRIPK1MAPTALDH1A1MEN1 | |
| SCHEMBL23800951 | 0.83 | RIPK1 (0.65) | POLBRIPK1MAPTALDH1A1MEN1 | |
| SCHEMBL21678867 | 0.80 | RIPK1 (1.00) | POLBRIPK1 | |
| SCHEMBL9370395 | 0.80 | RIPK1 (1.00) | POLBRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190135718-A1 | SMALL MOLECULE INHIBITORS OF NECROPTOSIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2019-05-09 | — | — | US | disclosed |
| US-20170305824-A1 | SMALL MOLECULE INHIBITORS OF NECROPTOSIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2017-10-26 | — | — | US | disclosed |
| US-20170305824-A1 | SMALL MOLECULE INHIBITORS OF NECROPTOSIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2017-10-26 | — | — | US | disclosed |
| US-9586880-B2 | Small molecule inhibitors of necroptosis | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586880-B2 | Small molecule inhibitors of necroptosis | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-03-07 | — | — | US | disclosed |
| EP-3000468-A1 | SMALL MOLECULE INHIBITORS OF NECROPTOSIS | President and Fellows of Harvard College (US) | 2016-03-30 | — | — | EP | disclosed |
| US-20140024657-A1 | SMALL MOLECULE INHIBITORS OF NECROPTOSIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-01-23 | — | — | US | disclosed |
| US-20140024657-A1 | SMALL MOLECULE INHIBITORS OF NECROPTOSIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-01-23 | — | — | US | disclosed |
| US-20120122889-A1 | SMALL MOLECULE INHIBITORS OF NECROPTOSIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122889-A1 | SMALL MOLECULE INHIBITORS OF NECROPTOSIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-05-17 | — | — | US | disclosed |
| WO-2010075561-A1 | SMALL MOLECULE INHIBITORS OF NECROPTOSIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122889-A1 | SMALL MOLECULE INHIBITORS OF NECROPTOSIS | TNF, TNFRSF1A, RIPK1 | POLB 2233/4885RIPK1 3/4885MAPT 2906/4885 |
| US-20170305824-A1 | SMALL MOLECULE INHIBITORS OF NECROPTOSIS | TNF, TNFRSF1A, RIPK1 | POLB 2287/4885RIPK1 3/4885MAPT 2940/4885 |
| US-20190135718-A1 | SMALL MOLECULE INHIBITORS OF NECROPTOSIS | TNF, TNFRSF1A, RIPK1 | POLB 2287/4885RIPK1 3/4885MAPT 2940/4885 |
| US-20140024657-A1 | SMALL MOLECULE INHIBITORS OF NECROPTOSIS | TNF, TNFRSF1A, RIPK1 | POLB 2287/4885RIPK1 3/4885MAPT 2940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.